生物系研究部沼津支所

研究業績

A cancer-specific anti-podoplanin monoclonal antibody, PMab-117-mG2a exerts antitumor activities in human tumor xenograft models.
T. Tanaka, H. Suzuki ,T. Ohishi, M. K. Kaneko, and Y. Kato
Cells, 2024, 13, 1833, https://doi.org/10.3390/cells13221833

Spencermartinsiella japonica f.a., sp. nov., a novel yeast species isolated from biofilm in a reverse osmosis system.
H. Doi, A. Mishima, and R. Ikeda
Mycoscience, 2024, 65, 224-227, doi: 10.47371/mycosci.2024.05.004

Enhanced anticancer activity of 7MeERT over Ertredin: a comparative study on cancer cell proliferation and NDUFA12 binding.
S. Atsumi, C. Nosaka, T. Onodera, H. Adachi, T. Watanabe, M. Kawada, M. Shibuya, S. I. Park, and H. J. Kwon
Biomolecules, 2024, 14, 1197. https://doi.org/10.3390/biom14091197

Antitumor activities of anti‑CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer.
K. Ishikawa, H. Suzuki, T. Ohishi, T. Nakamura, M. Yanaka, G. Li, T. Tanaka, A. Ohkoshi, M. Kawada, M. K. Kaneko, Y. Katori, and Y. Kato
Oncol Rep., 2024, 52, 147. doi: 10.3892/or.2024.8806.

Anti-CD44 variant 10 monoclonal antibody exerts antitumor activity in mouse xenograft models of oral squamous cell carcinomas.
K. Ishikawa, H. Suzuki, T. Ohishi, G. Li, T. Tanaka, M. Kawada, A. Ohkoshi, M. K. Kaneko, and Y. Kato
Int. J. Mol. Sci., 2024, 25, 9190, https://doi.org/10.3390/ijms25179190

Anti-HER2 cancer-specific mAb, H2Mab-250-hG1, possesses higher complement-dependent cytotoxicity than trastuzumab.
H. Suzuki, T. Ohishi, T. Tanaka, M. K. Kaneko, and Y. Kato
Int. J. Mol. Sci., 2024, 25, 8386, https://doi.org/10.3390/ijms25158386

Inhibition of kynurenine production by N, O-substituted hydroxylamine derivatives.
M. Iijima, Y. Otsuka, S. Ohba, and I. Momose
Bioorg. Med. Chem. Lett. 2024, 106, 129731

Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies.
T. Arimori , E. Mihara, H. Suzuki, T. Ohishi, T. Tanaka, M. K. Kaneko, J. Takagi, and Y. Kato
Structure, 2024, https://doi.org/10.1016/j.str.2024.02.007

A cancer-specific monoclonal antibody against HER2 exerts antitumor activities in human breast cancer xenograft models.
M. K. Kaneko., H. Suzuki, T. Ohishi, T. Nakamura, T. Tanaka, and Y. Kato
Int. J. Mol. Sci., 2024, 25, 1941. doi: 10.3390/ijms25031941

Pancreatic stromal cell-derived oncostatin M confers drug resistance to a multi-tyrosine kinase Inhibitor in pancreatic cancer cells.
D. Tatsuda, J. Yoshida, T. Ohishi, and M. Kawada
Anticancer Res. 2024, 43, 2477-2489. doi:10.21873/anticanres.16415

A cancer-specific monoclonal antibody against podocalyxin exerted antitumor activities in pancreatic cancer xenografts.
H. Suzuki, T. Ohishi, T. Tanaka, M. K. Kaneko, and Y. Kato
Int J. Mol. Sci. 2024, 25, 161. https://doi.org/10.3390/ijms25010161

Two new adenopeptins B and C inhibit sphere formation of pancreatic cancer cells.
D. Tatsuda, M. Amemiya, C. Nosaka, R. Sawa, H. Muramatsu, M. Igarashi, J. Yoshida, T. Ohishi, and M. Kawada
https://doi.org/10.1038/s41429-023-00679-y

Antitumor activities against breast cancers by an afucosylated anti-HER2 monoclonal antibody H2Mab-77-mG2a-f.
T. Tanaka, H. Suzuki, T. Ohishi, M. K. Kaneko, and Y. Kato
Cancer Science, 2023, 00:1-12. DOI: 10.1111/cas.16008

A humanized and defucosylated antibody against podoplanin(humLpMab-23-f) exerts antitumor activities in human lung cancer and glioblastoma xenograft models.
H. Suzuki, T. Ohishi, M. K. Kaneko, and Y. Kato
Cancers, 2023, 15, 5080. https://doi.org/10.3390/cancers15205080

Deoxynortryptoquivaline: A unique antiprostate cancer agent.
Y. Yamazaki, M. Kawada, and I. Momose
Oncology Research, 2023, 31, 845-853, Doi: 10.32604/or.2023.030266

Identification of a dihydroorotate dehydrogenase inhibitor that inhibits cancer cell growth by proteomic profiling.
M. Kawatani, H. Aono, S. Hiranuma, T. Shimizu, M. Muroi, T. Nogawa, T. Ohishi, S. I. Ohba, M. Kawada, K. Yamazaki, S. Dan, N. Dohmae, and H. Osada
Oncology Research, 2023, 31, 833-844, Doi: 10.32604/or.2023.030241

Defucosylated monoclonal antibody (H2Mab-139-mG2a-f) exerted antitumor activities in mouse xenograft models of breast cancers against human epidermal growth factor receptor 2.
H. Suzuki, T. Ohishi, R. Nanamiya, M. Kawada, M. K. Kaneko, and Y. Kato
Curr. Issues Mol. Biol. 2023, 45, 7734-7748. htps://doi.org/10.3390/cimb45100488

Anti-inflammatory effects of dietary polyphenols through inhibitory activity against metalloproteinases.
T. Suzuki, T. Ohishi, H. Tanabe, N. Miyoshi, and Y. Nakamura
Molecules 2023, 28, 5426. https://doi.org/10.3390/molecules28145426

Pancreatic stromal cell-derived oncostatin M confers drug resistance to a multi-tyrosine kinase inhibitor in pancreatic cancer cells.
D. Tatsuda, J. Yoshida, T. Ohishi and M. Kawada
Anticancer Res. 2023, 43, 2477-2489. doi:10.21873/anticanres.16415

がんエネルギー代謝を標的とした創薬
吉田潤次郎、大石智一、川田 学
腫瘍内科 2023, 31, 102-108

Current targeted therapy for metastatic colorectal cancer.
T. Ohishi, M. K. Kaneko, Y. Yoshida, A. Takashima, Y. Kato, and M. Kawada
Int. J. Mol. Sci., 2023, 24, 1702. https://doi.org/10.3390/ijms24021702

A specific G9a inhibitor unveils BGLT3 lncRNA as a universal mediator of chemically induced fetal globin gene expression.
S. Takase, T. Hiroyama, F. Shirai, Y. Maemoto, A. Nakata, M. Arata, S. Matsuoka, T. Sonoda, H. Niwa, S. Sato, T. Umehara, M. Shirouzu, Y. Nishigaya, T. Sumiya, N. Hashimoto, R. Namie, M. Usui, T. Ohishi, S. Ohba, M. Kawada, Y. Hayashi, H. Harada, T. Yamaguchi, Y. Shinkai, Y. Nakamura, M. Yoshida, and A. Ito
Nature Communications 2023. https://doi.org/10.1038/s41467-022-35404-0

Effects of epigallocatechin-3-gallate on matrix metalloproteinases in terms of its anticancer activity.
H. Tanabe, T. Suzuki, T. Ohishi, M. Isemura, Y. Nakamura, and K. Unno
Molecules, 2023, 28, 525. https://doi.org/10.3390/molecules28020525

Health effects of soy isoflavones and green tea catechins on cancer and cardiovascular diseases based on urinary biomarker levels.
T. Ohishi, N. Miyoshi, M. Mori, M. Sagara, and Y. Yamori
Molecules, 2022, 27, 8899. https:doi.org/10.3390/molecules27248899

Contribution of non-coding RNAs to anticancer effects of dietary polyphenols: chlorogenic acid, curcumin, epigallocatechin-3-gallate, genistein, quercetin and resveratrol.
S. Hayakawa, T. Ohishi, Y. Oishi, M. Isemura, and N. Miyoshi
Antioxidants, 2022, 11, 2352. https://doi.org/10.3390/antiox11122352

A defucosylated anti-EpCAM monoclonal antibody (EpMab-37-mG2a-f) exerts antitumor activity in xenograft model.
T. Asano, T. Tanaka, H. Suzuki, G. Li, T. Ohishi, M. Kawada, T. Yoshikawa, M. K. Kaneko, and Y. Kato
Antibodies, 2022, 11, 74. https://doi.org/10.3390/antib11040074

Defucosylated mouse-dog chimeric anti-HER2 monoclonal antibody (H77Bf) exerts antitumor activities in mouse xenograft models of canine osteosarcoma.
R. Nanamiya, T. Ohishi, H. Suzuki, T. Mizuno, T. Yoshikawa, T. Asano, T. Tanaka, M. K. Kaneko, and Y. Kato
Monoclon. Antib. Immunodiagn. Immunother., 2022. doi: 10.1089/mab.2022.0022

Antitumor activity of an anti-EGFR/HER2 bispecific antibody in a mouse xenograft model of canine osteosarcoma.
N. Tateyama, H. Suzuki, T. Ohishi, T. Asano, T. Tanaka, T. Mizuno, T. Yoshikawa, M. Kawada, M. K. Kaneko, and Y. Kato
Pharmaceutics, 14, 2494, https://doi.org/10.3390/pharmaceutics14112494

Antitumor activities in mouse xenograft models of canine fibroblastic tumor by defucosylated mouse-dog chimeric anti-HER2 monoclonal antibody (H77Bf).
H. Suzuki, T. Asano, T. Ohishi, T. Yoshikawa, H. Suzuki, T. Mizuno, T. Tanaka, M. Kawada, M. K. Kaneko, and Y. Kato
Monoclon. Antib. Immunodiagn. Immunother., 2022. doi: 10.1089/mab.2022.0023

Antisense gapmers with LNA-wings and (S)-5′-C-aminopropyl-2-arabinofluoro-nucleosides could efficiently suppress the expression of KNTC2.
Y. Zhou, S. Sakamoto and Y. Ueno
Molecules, 2022, 27, 7384. doi: 10.3390/molecules27217384

Anti‑lung cancer properties of cyanobacterial bioactive compounds.
M. S. Baig, S. Rajpoot, T. Ohishi, R. Savai, S. Seidel, N. A. Kamennaya, E. E. Bezsonov, A. N. Orekhov, P. Mahajan, K. Solanki, and U. Saqib
Archives of Microbiology, 2022, 204, 606. https://doi.org/10.1007/s00203-022-03194-0

Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancer.
Y. Kubota, Y. Fujioka, A. Patil, Y. Takagi, D. Matsubara, M. Iijima, I. Momose, R. Naka, K. Nakai, N. N. Noda, and M. Takekawa
Nat. Commun., 2022, 13, 4063. doi: 10.1038/s41467-022-31690-w.

Structural analysis of spike proteins from SARS-CoV-2 variants of concern highlighting their functional alterations.
K. Solanki, S. Rajpoot, A. Kumar, K. Y J Zhang, T. Ohishi, N. Hirani, K. Wadhonkar, P. Patidar, Q. Pan, and M. S Baig
Future Virol. 2022, Jul; 10.2217/fvl-2022-0003. doi: 10.2217/fvl-2022-0003.

Defucosylated mouse‑dog chimeric anti‑HER2 monoclonal antibody exerts antitumor activities in mouse xenograft models of canine tumors.
H. Suzuki, T. Ohishi, T. Asano, T. Tanaka, M. Saito, T. Mizuno, T. Yoshikawa, M. Kawada, M. K. Kaneko, and Y. Kato
Oncol. Rep., 2022, 48, 154. doi: 10.3892/or.2022.8366

Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2.
T. Ohishi, T. Hishiki, M. S. Baig, S. Rajpoot, U. Saquib, T. Takasaki, and Y. Hara
Plos One. 2022, 17, e0271112. doi: 10.1371/journal.pone.0271112. eCollection 2022

Anti-cancer effects of dietary polyphenols via ROS-mediated pathway with their modulation of microRNAs.
Y. Yoshioka, T. Ohishi, Y. Nakamura, R. Fukutomi and N. Miyoshi
Molecules 2022, 27, 3816. https://doi.org/10.3390/molecules27123816

Defucosylated anti-EGFR monoclonal antibody exerted antitumor activities in mouse xenograft models of canine mammary gland tumor.
T. Tanaka, T, Ohishi, M. Saito, H. Suzuki, M. K. Kaneko, M. Kawada, and Y. Kato
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2022, 41, 142-149. doi: 10. 1089/mab. 2022. 0009

A defucosylated mouse anti-CD10 monoclonal antibody (31-mG2a-f) exerts antitumor activity in a mouse xenograft model of renal cell cancers.
H. Kawabata, T. Ohishi, H. Suzuki, T. Asano, M. Kawada, H. Suzuki, M. K. Kaneko and Y. Kato
Monoclon. Antib. Immunodiagn. Immunother. 2022. doi. org/10. 1089/mab. 2021. 0049. PMID: 35483055

A defucosylated mouse anti-CD10 monoclonal antibody (31-mG2a-f) exerts antitumor activity in a mouse xenograft model of CD10-overexpressed tumors.
H. Kawabata, H. Suzuki, T. Ohishi, M. kawada, M. K. Kaneko and Y. Kato
Monoclon Antib Immunodiagn Immunother. 2022. 41. 59-66. doi: 10. 1089/mab. 2021. 0048. PMID: 35471051

Antitumor activities in mouse xenograft models of canine mammary gland tumor by defucosylated mouse-dog chimeric anti-EGFR antibody (E134Bf).
G. Li, H. Suzuki, J. Takei, T. Asano, M. Sano, T. Tanaka, H. Harada, T. Mizuno, T. Ohishi, M. Kawada, M. K. Kaneko and Y. Kato
Monoclon Antib Immunodiagn Immunother. 2022, 41, 53-58. doi: 10. 1089/mab. 2021. 0040. PMID: 35471048

Synthesis, gene silencing activity, thermal stability, and serum stability of siRNA containing four (S)-5’-C-aminopropyl-2’-O-methylnucleosides (A, adenosine; U, uridine; G, guanosine; and C, cytidine).
R. Kajino, S. Sakamoto and Y. Ueno
RSC Advances, 2022, 12, 11454. doi.org/10.1039/D2RA00705C

Antitumor activities in mouse xenograft models of canine fibroblastic tumor by defucosylated anti-EGFR monoclonal antibody.
N. Goto, H. Suzuki, T. Ohishi, A. Harakawa, G. Li, M. Saito, J. Takei, T. Tanaka, T. Asano, M. Sano, M. Kawada, M. Kaneko, and Y. Kato
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2022, 42, doi: 10.1089/mab.2021.0059

Rediscovery of 4-trehalosamine as a biologically stable, mass-producible, and chemically modifiable trehalose analog.
S. Wada, H. Arimura, M. Nagayoshi, R. Sawa, Y. Kubota, K. Matoba, C. Hayashi, Y. Shibuya, M. Hatano, Y. Takehana, S. Ohba, Y. Kobayashi, T. Watanabe, M. Shibasaki, and M. Igarashi
Advanced Biology 2022, 6, 2101309, https://doi.org/10.1002/adbi. 202101309

Involvement of microRNA modifications in anticancer effects of major polyphenols from green tea, coffee, wine, and curry.
T. Ohishi, S. Hayakawa and N. Miyoshi
Critical Reviews in Food Science and Nutrition. 2022, 62, https://doi.org/10.1080/10408398. 2022. 2038540

TrMab-6 exerts antitumor activity in mouse xenograft models of breast cancers.
T. Tanaka, T. Ohishi, M. Saito, M. Kawada, M. K. Kaneko and Y. Kato
Monoclon Antib Immunodiagn Immunother. 2022, 41, 32-38. doi:10.1089/mab.2021.0056. PMID: 35225665

Defucosylated anti-EGFR monoclonal antibody (134-mG2a-f) exerts antitumor activities in mouse xenograft models of canine osteosarcoma.
R. Nanamiya, J. Takei, T. Ohishi, T. Asano, T. Tanaka, M. Sano, T. Nakamura, M. Yanaka, S. Handa, Y. Komatsu, H. Hosono, N. Tateyama, Y. Harigae, M. Saito, H. Suzuki, M. Kawada, M. K. Kaneko and Y. Kato
Monoclon Antib Immunodiagn Immunother. 2022, 41, 1-7. doi: 10.1089/mab.2021.0036. PMID: 35225663

Isolation of new derivatives of the 20-membered macrodiolide bispolide from Kitasatospora sp. MG372-hF19.
Y. Kohda, S. Sakamoto, M. Umekita, T. Kimura, Y. Kubota, R. Arisaka, Y. Shibuya, H. Muramatsu, R. Sawa, S. Dan, M. Kawada, and M. Igarashi.
J. Antibiot., 2022, 75, 77-85. doi.org/10.1038/s41429-021-00492-5

Defucosylated mouse-dog chimeric anti-EGFR antibody exerts antitumor activities in mouse xenograft models of canine tumors.
G. Li, T. Ohishi, M. K. Kaneko, J. Takei, T. Mizuno, M. Kawada, M. Saito, H. Suzuki and Y. Kato
Cells, 2021, 10, 3599.

Mitochondrial complex I inhibitors suppress tumor growth through concomitant acidification of the intra- and extracellular environment
J. Yoshida, T. Ohishi, H. Abe, S. Ohba, H. Inoue, I. Usami, M. Amemiya, R. Oriez, C. Sakashita, S. Dan, M. Sugawara, T. Kawaguchi, J. Ueno, Y. Asano, A. Ikeda, M. Takamatsu, G. Amori, Y. Kondoh, K. Honda, H. Osada, T. Noda, T. Watanabe, T. Shimizu, M. Shibasaki, M. Kawada.
iScience, 2021, 24, 103497. doi.org/10.1016/ j.isci.2021.103497

Identification of dihydroorotate dehydrogenase inhibitors-indoluidins-that inhibit cancer cell growth.
M. Kawatani, H. Aono, T. Shimizu, S. Ohkura, S. Hiranuma, M. Muroi, N. Ogawa, T. Ohishi, SI. Ohba, M. Kawada, K. Yamazaki, S. Dan and H. Osada
ACS Chem. Biol. 2021, 16, 2570-2580, doi: 10.1021/acschembio.1c00625

Structure-activity relationships of natural quinone vegfrecine analogs with potent activity against VEGFR-1 and -2 tyrosine kinases.
H. Adachi, C. Nosaka, S. Atsumi, K. Nakae, Y. Umezawa, R. Sawa, Y. Kubota, C. Nakane, M. Shibuya and Y. Nishimura
J. Antibiot., 2021, 74, 734-742.

Quinofuracins F - I, new quinofuracin derivatives produced by Staphylotrichum boninense PF1444.
D. Tatsuda, M. Amemiya, R. Sawa, I. Momose and M. Kawada
J. Antibiot., 2021, 74, 758-762.

Metacytofilin has potent anti-malarial activity.
A. Leesombun, M. Iijima, B. Pagmadulam, B. Orkhon, H. Doi, K. Issiki, R. Sawa, CI. Nihei and Y. Nishikawa.
Parasitol Int., 2021, 81, 2021 doi: 10.1016/j.parint.2020.102267.

Androprostamine A: a unique antiprostate cancer agent.
Y. Yamazaki, H. Abe, C. Sakashita, SI. Ohba, T. Watanabe, I. Momose and M. Kawada.
J. Antibiot., 2021, 74, 717-725.

The beneficial effects of principal polyphenols from green Tea, coffee, wine, and curry on obesity.
T. Ohishi, R. Fukutomi, Y. Shoji, S. Goto and M. Isemura
Molecules, 2021, 26, 453.

金化合物Auranofinのがん微小環境特異的抗がん活性
百瀬 功、小野寺威文、川田 学
YAKUGAKU ZASSHI, 2021, 141(3), 315-321.

Metacytofilin is a potent therapeutic drug candidate for toxoplasmosis
A. Leesombun, M. Iijima, K. Umeda, D. Kondoh, B. Pagmadulam, A. M Abdou, Y. Suzuki, S. Ohba, K. Isshiki, T. Kimura, Y. Kubota, R. Sawa, CI. Nihei, Y. Nishikawa.
The Journal of Infectious Diseases, 2020, 221, 766-774

Interferon-induced transmembrane protein 1 (IFITM1) promotes distant metastasis of small cell lung cancer.
S. Sakamoto, H. Inoue, Y. Kohda, S. Ohba, T. Mizutani, and M. Kawada
Int. J. Mol. Sci., 2020, Vol. 21, 4934.

A defucosylated anti-PD-L1 monoclonal antibody 13-mG 2a-f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
J. Takei, T. Ohishi, M. K. Kaneko, H. Harada, M. Kawada and Y. Kato
Biochem. Biophys. Rep., 2020, 24. 100801. doi: 10.1016/j.bbrep.2020.100801.

ボロン酸を利用したがん分子標的治療薬の開発
百瀬 功、渡辺 匠
ファルマシア, 2020, Vol. 56, 416-420.

Human pancreatic cancer cells under nutrient deprivation are vulnerable to redox system inhibition.
T. Onodera, I. Momose, H. Adachi, Y. Yamazaki, R. Sawa, SI. Ohba and M. Kawada
J. Biol. Chem., 2020, 295, 16678-16690.

A novel anti-EGFR monoclonal antibody (EMab-17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
J. Takei, MK. Kaneko, T. Ohishi, M. Kawada, H. Harada and Y. Kato
Oncol. Lett., 2020, 19, 2809-2816.

A new indole glycoside from Kitasatospora sp. MG372-hF19 carrying a 6 deoxy-α-l-talopyranose moiety
Y. Kohda, S. Sakamoto, Y. Otsuka, R. Sawa, Y. Kubota, M. Igarashi, H. Muramatsu, M. Iijima and M. Kawada
J. Antibiot., 2020, 73, 167-170.

Potent antibiotics active against multidrug-resistant gram-negative bacteria
Y. Otsuka
Chem. Pharm. Bull., 2020, 68, 182-190.

Inhibition of mitochondria ATP synthase suppresses prostate cancer growth through reduced insulin-like growth factor-1 secretion by prostate stromal cells.
T. Ohishi, H. Abe, C. Sakashita, U. Saqib, MS. Baig, SI. Ohba, H. Inoue, T. Watanabe, M. Shibasaki and M. Kawada.
Int. J. Cancer., 2020, 146, 3474-3484.

Tumor-derived exosomes in the regulation of macrophage polarization.
MS. Baig, A. Roy, S. Rajpoot, D. Liu, R. Savai, S. Banerjee, M. Kawada, SM. Faisal, R. Saluja, U. Saqib, T. Ohishi and KK. Wary.
Inflamm Res. 2020, 69, 435-451

Antibody-drug conjugates using mouse-canine chimeric anti-dog podoplanin antibody exerts antitumor activity in a mouse xenograft model.
Y. Kato, Y. Ito, T. Ohishi, M. Kawada, T. Nakamura, Y. Sayama, M. Sano, T. Asano, M. Yanaka, S. Okamoto, S. Handa, Y. Komatsu, J. Takei and MK. Kaneko.
Monoclon Antib Immunodiagn Immunother., 2020, 39, 37-44

Description of Gelidibacter japonicus sp. nov., isolated from the Inland Sea (Setonaikai) in Japan.
H. Doi and I. Osawa
Archives of Microbiology 2019, 201, 1019-1024. doi:https://doi.org/10.1007/s00203-019-01668-2

Anti-human EGFR 2 monoclonal antibody H2Mab-41 exerts antitumor activity in a mouse xenograft model of colon cancer.
Y. Kato, T. Ohishi, S. Yamada, S. Itai, J. Takei, M. Sano, T. Nakamura, H. Harada, M. Kawada and MK. Kaneko
Monoclon. Antib. Immunodiagn. Immunother., 2019, 38, 157-161.

Anti-CD133 monoclonal antibody CMab-43 exerts antitumor activity in a mouse xenograft model of colon cancer.
Y. Kato, T. Ohishi, S. Yamada, S. Itai, Y. Furusawa, M. Sano, T. Nakamura, M. Kawada and MK. Kaneko
Monoclon. Antib. Immunodiagn. Immunother., 2019, 38, 75-78.

Leucinostatin Y: A peptaibiotic produced by the entomoparasitic fungus Purpureocillium lilacinum 40-H-28.
I. Momose, T. Onodera, H. Doi, H. Adachi, M. Iijima, Y. Yamazaki, R. Sawa, Y. Kubota, M. Igarashi and M. Kawada
J. Nat. Prod. 2019, 82, 1120-1127

Potential anticancer activity of auranofin.
T. Onodera, I. Momose and M. Kawada
Chem. Pharm. Bull. 2019, 67, 186-191

優占化した海洋性繊毛虫を利用した塩分含有廃水の処理技術
土井宏育
Bull. Soc. Sea Water Sci., Jpn., 2019, 73, 271 -272.

Generation and evaluation of a chimeric antibody against coxsackievirus and adenovirus receptor for cancer therapy
S. Sakamoto, H. Inoue, M. K. Kaneko, S. Ogasawara, M. Kajikawa, S. Urano, S. Ohba, Y. Kato and M. Kawada
Cancer Sci., 2019, 110, 3595-3602.

The mouse–canine chimeric anti-dog podoplanin antibody P38B exerts antitumor activity in mouse xenograft models.
Y. Kato, T. Ohishi, M. Kawada, N. Maekawa, S. Konnai, S. Itai, S. Yamada and MK. Kaneko
Biochem Biophys Rep. 2019, 17, 23-26

Calpain-10 regulates actin dynamics by proteolysis of microtubule-associated protein 1B.
T. Hatta, SI. Iemura, T. Ohishi, H. Nakayama, H. Seimiya, T. Yasuda, K. Iizuka, M. Fukuda, J. Takeda, T. Natsume and Y. Horikawa.
Sci Rep., 2018, 8:16756, doi: 10.1038/s41598-018-35204-x.

Monotherapy with a novel intervenolin derivative, AS-1934, is an effective treatment for Helicobacter pylori infection.
T. Ohishi, T. Masuda, H. Abe, C. Hayashi, H. Adachi, S. Ohba, M. Igarashi, T. Watanabe, H. Mimuro, E. Amalia, DK. Inaoka, K. Mochizuki, K. Kita, M. Shibasaki and M. Kawada
Helicobacter 2018, 23, e12470

A guanine derivative as a new MEK inhibitor produced by Streptomyces sp. MK63-43F2.
M. Iijima, Yuji Kubota, R. Sawa, Yumiko Kubota, M. Hatano, M. Igarashi, M. Kawada, I. Momose, M. Takekawa and M. Shibasaki
J. Antibiot. 2018, 71, 135-138

Microbial metabolites and derivatives targeted at inflammation and bone diseases therapy: chemistry, biological activity and pharmacology.
H. Adachi, K. Nakae, S. Sakamoto, C. Nosaka, S. Atsumi, M. Shibuya, N. Higashi, M. Nakajima, T. Irimura and Y. Nishimura
J. Antibiot. 2018, 71, 60-71

Novel approaches for identification of anti-tumor drugs and new bioactive compounds.
M. Kawada, S. Atsumi, S. Wada and S. Sakamoto
J. Antibiot. 2018, 71, 39-44

Phenazine carboxylic acid and its derivative induce osteoblast differentiation in preosteoblastic MC3T3-E1 cells but adipocyte differentiation in pluripotent mesenchymal C3H10T1/2 cells.
S. Sakamoto, T. Watanabe, Y. Kohda, M. Iijima, R. Sawa, M. Okada, H. Adachi, Y. Nishimura, M. Kawada
J. Antibiot. 2017, 70, 1146-1149

Tyropeptins, proteasome inhibitors produced by Kitasatospora sp. MK993-dF2.
I. Momose and T. Watanabe
J. Antibiot. 2017, 70, 542-550.

Acremopeptin, a new peptaibol from Acremonium sp. PF1450.
M. Iijima, M. Amemiya, R. Sawa, Y. Kubota, T. Kunisada, I. Momose, M. Kawada and M. Shibasaki
J. Antibiot. 2017, 70, 791-794

Vibrio japonicus sp. nov.,a novel member of the Nereis clade in the genus Vibrio isolated from the coast of Japan.
H. Doi, I. Osawa, H. Adachi and M. Kawada
PLoS ONE 12(2):e0172164. 2017, doi: 10.1371/journal.pone.0172164

A novel monoclonal antibody targeting coxsackie virus and adenovirus receptor inhibits tumor growth in vivo
M. Kawada, H. Inoue, M. Kajikawa, M. Sugiura, S. Sakamoto, S. Urano, C. Karasawa, I. Usami, M. Futakuchi and T. Masuda.
Sci. Rep. 2017, 7:40400 doi: 10.1038/srep40400.

Small molecules modulating tumor-stromal cell interactions: new candidates for anti-tumor drugs.
M. Kawada
J. Antibiot. 2016, 69, 411-414.

An iminosugar-based heparanase inhibitor heparastatin (SF4) suppresses infiltration of neutrophils and monocytes into Inflamed dorsal air pouches.
M. Sue, N. Higashi, H. Shida, Y. Kogane, Y. Nishimura, H. Adachi, E. Kolaczkowska, M. Kepka, M. Nakajima and T. Irimura
Int. immunopharmacology. 2016, 35, 15-21.

Biological activities of unique isoflavones prepared from Apios americana Medik.
H. Kaneta, M. Koda, S. Saito, M. Imoto, M. Kawada, Y. Yamazaki, I. Momose and K. Shindo.
Biosci Biotechnol Biochem. 2016, 80, 774-778.

Synthesis of androprostamine A and resormycin.
H. Abe, Y. Yamazaki, C. Sakashita, I. Momose, T. Watanabe and M. Shibasaki.
Chem. Pharm. Bull. 2016, 64, 982-987.

Heparanase augments inflammatory chemokine production from colorectal carcinoma cell lines.
N. Tsunekawa, N. Higashi, Y. Kogane, M. Waki, H. Shida, Y. Nishimura, H. Adachi, M. Nakajima and T. Irimura.
Biochem. Biophys. Res. Commun. 2016, 469, 873-883.

Report on the use of non-clinical studies in the regulatory evalution of oncology drugs.
Y. Hayakawa, M. Kawada, H. Nishikawa, T. Ochiya, H. Saya, H. Seimiya, R. Yao, M. Hayashi, C. Kai, A. Matsuda, T. Naoe, A. Ohtsu, T. Okazaki, H. Saji, M. Sata, H. Sugimura, Y. Sugiyama, M. Toi and T. Irimura.
Cancer Sci. 2016, 107, 189-202.

Heparanase augments inflammatory chemokine production from colorectal carcinoma cell lines.
N. Tsunekawa, N. Higashi, Y. Kogane, M. Waki, H. Shida, Y. Nishimura, H. Adachi, M. Nakajima and T. Irimura.
Biochem. Biophys. Res. Commun. 2016, 469, 873-883.

The therapeutic potential of microbial proteasome inhibitors.
I. Momose and M. Kawada.
Int Immunopharmacol. 2016, 37, 23-30.

Coccoquinones A and B, new anthraquinone derivatives produced by Staphylotrichum coccosporum PF1460
D. Tatsuda, M. Amemiya, R. Sawa, K. Sumiyoshi, T. Watanabe, I. Momose, M. Kawada, A. Nomoto and M. Shibasaki.
J. Antibiot. 2016, 69, 176-178.

BNew anti-cancer chemicals Ertredin and its derivatives, regulate oxidative phosphorylation and glycolysis and suppress sphere formation in vitro and tumor growth in EGFRvIII-transformed cells.
S. Atsumi, C. Nosaka, H. Adachi, T. Kimura, Y. Kobayashi, H. Takada, T. Watanabe, S. Ohba, H. Inoue, M. Kawada, M. Shibasaki, M. Shibuya.
BMC Cancer., 19, 496, 2016.

A novel anti-microtubule agent with carbazole and benzohydrazide structures suppresses tumor cell growth in vivo.
M. Ohira, Y. Iwasaki, C. Tanaka, M. Kuroki, N. Matsuo, T. Kitamura, M. Yukuhiro, H. Morimoto, N. Pang, B. Liu, T. Kiyono, M. Amemiya, K. Tanaka, K. Yoshida, N. Sugimoto, T. Ohshima and M. Fujita.
Biochim Biophys Acta. 2015, 1850, 1676-1684

がんと間質の相互作用を利用したがんの抑制
川田　学、吉田潤次郎、坂本修一
実験医学（増刊）2015, 33, 199-203

New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice.
S. Sakamoto, H. Inoue, S. Ohba, Y. Kohda, I. Usami, T. Masuda, M. Kawada and A. Nomoto.
Cancer Science.2015，106，367-374

Quinofuracins A-E, produced by the fungus staphylotrichum boninense PF1444, show p53-dependent growth suppression.
D. Tatsuda, I. Momose, T. Someno, R. Sawa, Y. Kubota, M. Iijima, T. Kunisada, T. Watanabe, M. Shibasaki and A. Nomoto.
J. Nat. Prod. 2015, 78, 188-195

Complete stereochemistry and preliminary structure-activity relationship of rakicidin A, a hypoxia-selective cytotoxin from micromonospora sp.
N. Oku, S. Matoba, YM. Yamazaki, R. Shimasaki, S. Miyanaga and Y. Igarashi.
J. Nat. Prod. 2014, 77, 2561-2565.

Antitumor effects of tyropeptin-boronic acid derivatives: new proteasome inhibitors.
I. Momose, H. Abe, T. Watanabe, S. Ohba, K. Yamazaki, S. Dan, T. Yamori, T. Masuda and A. Nomoto
Cancer Sci. 2014, 105, 1609-1615.

Asteltoxins from the entomopathogenic fungus pochonia bulbillosa 8-H-28.
H. Adachi, H. Doi, Y. Kasahara, R. Sawa, K. Nakajima, Y. Kubota, N. Hosokawa, K. Tateishi and A. Nomoto.
J. Nat. Prod. 2015,78,1730-1734

Androprostamines A and B, the new anti-prostate cancer agents produced by Streptomyces sp. MK932-CF8.
Y. Yamazaki, T. Someno, M. Igarashi, N. Kinoshita, M. Hatano, M. Kawada, I.Momose and
A. Nomoto.
J. Antibiot. 2014, 68, 279-285

Inhibition of protein SUMOylation by davidiin, an ellagitannin from Davidia involucrate.
M. Takemoto, Y. Kawamura, M. Hirohama, Y. Yamaguchi, H. Handa, H. Saitoh, Y. Nakao, M Kawada, K. Khalid, H. Koshino, K. Kimura, A. Ito and M. Yoshida.
J. Antibiot., 2014, 67, 335-338.

A new cell line from the fat body of Spodoptera litura (Lepidoptera, Noctuidae) and detection of lysozyme activity release upon immune stimulation.
K. Tateishi, Y. Kasahara, K. Watanabe, N. Hosokawa, H. Doi, K. Nakajima, H. Adachi and A. Nomoto.
In. Vitro. Cell. Dev. Bio. – An. 2014, 51, 15-18.

Structure and biological properties of lentztrehalose: a novel trehalose analog.
S. Wada, S. Ohba, T. Someno, M. Hatano and A. Nomoto.
J. Antibiot. 2013, 67, 319-322.

Modulation of tumor-stromal cell interactions: a new anti-tumor strategy targeting the tumor microenvironment.
M. Kawada, S. Sakamoto and A. Nomoto.
Forum on Immunopathological Diseases and Therapeutics 2013, 4, 53-62.

がん－間質相互作用を介したがん細胞の増殖抑制
川田学、坂本修一
Medical Science Digest 2013, 39, 24-27.

Synthesis of intervenolin, an antitumor natural quinolone with unusual substituents.
H. Abe, M. Kawada, H. Inoue, S. Ohba, A. Nomoto, T. Watanabe and M. Shibasaki.
Org. Lett. 2013, 15, 2124-2127.

Structure-activity relationship study of intervenolin derivatives: synthesis, antitumor and anti-Helicobacter Pylori activities.
H. Abe, M. Kawada, H. Inoue, S. Ohba, T. Masuda, C. Hayashi, M. Igarashi, A. Nomoto, T. Watanabe and M. Shibasaki.
Tetrahedron 2013, 69, 7608-7617.

Intervenolin, a new antitumor compound with anti-Helicobacter pylori activity, from Nocardia sp. ML96-86F2.
M. Kawada, H. Inoue, S. Ohba, M. Hatano, M. Amemiya, C. Hayashi, I. Usami, H. Abe, T. Watanabe, N. Kinoshita, M. Igarashi, T. Masuda, D. Ikeda and A. Nomoto.
J. Antibiot. 2013, 66, 543-548.

Sacchathridine A, a prostaglandin release inhibitor from Saccharothrix sp.
K. Nakae, I. Kurata, F. Kojima, M. Igarashi, M. Hatano, R. Sawa, Y. Kubota, H. Adachi and A. Nomoto.
J. Natural Products 2013, 76, 720-722.

NAD(P)H quinone oxidoreductase 1 (NQO1)-bioactivated pronqodine A regulates prostaglandin release from human synovial sarcoma cells.
K. Nakae, H. Adachi, R. Sawa, N. Hosokawa, M. Hatano, M. Igarashi, Y. Nishimura, Y. Akamatsu and A. Nomoto.
J. Natural Products 2013, 76, 510-515.

Amycolamicin: a novel broad-spectrum antibiotic inhibiting bacterial topoisomerase.
R. Sawa, Y. Takahashi, H. Hashizume, K. Sasaki, Y. Ishizaki, M.Umekita, M. Hatano, H. Abe, T. Watanabe, N. Kinoshita, Y. Homma, C. Hayashi, K. Inoue, S. Ohba, T. Masuda, M. Arakawa, Y. Kobayashi, M. Hamada, M. Igarashi, H. Adachi, Y. Nishimura and Y. Akamatsu.
Chem. Eur. J. 2012, 18, 15772-15781.

In vivo imaging of proteasome inhibition using a proteasome-sensitive fluorescent reporter.
I. Momose, D. Tatsuda, S. Ohba, T. Masuda, D. Ikeda and A. Nomoto.
Cancer Sci. 2012, 103, 1730-1736.

Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
K. Kimura, Y. Sakamoto, N. Fujisawa, S. Uesugi, N. Aburai, M. Kawada, S. Ohba, T. Yamori, E. Tsuchiya and H. Koshino.
Bioorg. Med. Chem. 2012, 20, 3887-3897.

Decalpenic acid induces early osteoblastic markers in pluripotent mesenchymal cells via activation of retinoic acid receptor gamma.
S. Sakamoto, F. Kojima, I. Momose, M. Kawada, H. Adachi and Y. Nishimura.
Biochem. Biophys. Res. Commun. 2012, 422, 751-757.

Tripropeptin C blocks the lipid cycle of cell wall biosynthesis by complex formation with undecaprenyl pyrophosphate.
H. Hashizume, R. Sawa, S. Harada, M. Igarashi, H. Adachi, Y. Nishimura and A. Nomoto.
Antimicrob. Agents Chemother. 2011, 55, 3821-3828.

Decalpenic acid, a novel small molecule from Penicillium verruculosum CR37010, induces early osteoblastic markers in pluripotent mesenchymal cells.
S. Sakamoto, F. Kojima, M. Igarashi, R. Sawa, M. Umekita, Y. Kubota, K. Nakae, S. Yamaguchi, H. Adachi, Y. Nishimura and Y. Akamatsu.
J. Antibiot. 2010, 63, 703-708.

Increased ABCB1 expression in TP-110-resistant RPMI-8226 cells.
M. Iijima, I. Momose and D. Ikeda.
Biosci. Biotechnol. Biochem. 2010, 74, 1913-1919.

Structure-activity relationship of boronic acid derivatives of tyropeptin: proteasome inhibitors.
T. Watanabe, H. Abe, I. Momose, Y. Takahashi, D. Ikeda and Y. Akamatsu.
Bioorg. Med. Chem. Lett. 2010, 20, 5839-5842.

Citric acid inhibits a bacterial ceramidase and alleviates atopic dermatitis in an animal
model.
H. Inoue, T. Someno, M. Kawada and D. Ikeda.
J. Antibiot. 2010, 63, 611-613.

NBRI16716A, a new antitumor compound against human prostate cancer cells, produced by Perisporiopsis melioloides Mer-f16716.
M. Kawada, T. Someno, H. Inoue, S. Ohba, T. Masuda, T. Kato and D. Ikeda.
J. Antibiot. 2010, 63, 319-323.

NBRI17671, a new antitumor compound, produced by Acremonium sp. CR17671.
M. Kawada, I. Usami, T. Someno, T. Watanabe, H. Abe, H. Inoue, S. Ohba, T. Masuda, Y. Tabata, S. Yamaguchi and D. Ikeda.
J. Antibiot. 2010, 63, 237-243.

Mitochondrial inhibitors show preferential cytotoxicity to human pancreatic cancer PANC-1 cells under glucose-deprived conditions.
I. Momose, S. Ohba, D. Tatsuda, M. Kawada, T. Masuda, G. Tsujiuchi, T. Yamori, H. Esumi and D. Ikeda.
Biochem. Biophys. Res. Commun. 2010, 392, 460-466.

Rubratoxin A specifically and potently inhibits protein phosphatase 2A and suppresses cancer metastasis.
S. Wada, I. Usami, Y. Umezawa, H. Inoue, S. Ohba, T. Someno, M. Kawada and D. Ikeda.
Cancer Sci. 2010, 101, 743-750.

Leucinostatin A inhibits prostate cancer growth through reduction of insulin-like growth factor-I expression in prostate stromal cells.
M. Kawada, H. Inoue, S. Ohba, T. Masuda, I. Momose and D. Ikeda.
Int. J. Cancer 2010, 126, 810-818.

Biological activities of pargamicin A, a novel cyclic peptide antibiotic from Amycolatopsis sp.
H. Hashizume, H. Adachi, M. Igarashi, Y. Nishimura and Y. Akamatsu.
J. Antibiot. 2010, 63, 279-283.

Antipain Y, a new antipain analog that inhibits neurotransmitter release from rat dorsal root ganglion neurons.
K. Nakae, F. Kojima, R. Sawa, Y. Kubota, M. Igarashi, N. Kinoshita, H. Adachi, Y. Nishimura and Y. Akamatsu.
J. Antibiot. 2010, 63, 41-44.

TP-110, a new proteasome inhibitor, down-regulates IAPs in human multiple myeloma cells.
M. Iijima, I. Momose and D. Ikeda.
Anticancer Res. 2009, 29, 977-985.

Synthesis of boronic acid derivatives of tyropeptin: proteasome inhibitors.
T. Watanabe, I. Momose, M. Abe, H. Abe, R. Sawa, Y. Umezawa, D. Ikeda, Y. Takahashi and Y. Akamatsu.
Bioorg. Med. Chem. Lett. 2009, 19, 2343-2345.

New atpenins, NBRI23477 A and B, inhibit the growth of human prostate cancer cells.
M. Kawada, I. Momose, T. Someno, G. Tsujiuchi and D. Ikeda.
J. Antibiot. 2009, 62, 243-246.

Inhibitors of insulin-like growth factor-1 receptor tyrosine kinase are preferentially cytotoxic to nutrient-deprived pancreatic cancer cells.
I. Momose, S. Kunimoto, M. Osono and D. Ikeda.
Biochem. Biophys. Res. Commun. 2009, 380, 171-176.

Ceramidastin, a novel bacterial ceramidase inhibitor, produced by Penicillium sp. Mer-f17067.
H. Inoue, T. Someno, T. Kato, H. Kumagai, M. Kawada and D. Ikeda.
J. Antibiot. 2009, 62, 63-67.

Phthoxazolin A inhibits prostate cancer growth by modulating tumor-stromal cell interactions.
M. Kawada, H. Inoue, I. Usami and D. Ikeda.
Cancer Sci. 2009, 100, 150-157.

酵素を用いたクラゲ処理の研究
今井俊明, 武田美貴雄, 土井宏育
火力原子力発電 2009, 60, 2-6.

A new type of tripropeptin with anteiso-branched chain fatty acid from Lysobacter sp. BMK333-48F3.
H. Hashizume, M. Igarashi, R. Sawa, H. Adachi, Y. Nishimura and Y. Akamatsu.
J. Antibiot. 2008, 61, 577-582.

A new terrein glucoside, a novel inhibitor of angiogenin secretion in tumor angiogenesis.
M. Arakawa, T. Someno, M. Kawada and D. Ikeda.
J. Antibiot. 2008, 61, 442-448.

Transforming growth factor-β1 modulates tumor-stromal cell interactions of prostate cancer through insulin-like growth factor-I.
M. Kawada, H. Inoue, M. Arakawa and D. Ikeda.
Anticancer Res. 2008, 28, 721-730.

Structure-activity relation study of 8-amino-2, 8-dideoxy-β-KDO, a potent CMP-KDO synthetase inhibitor.
H. Adachi, K. Kondo, F. Kojima, Y. Umezawa, K. Ishino, K. Hotta, Y. Nishimura and Y. Akamatsu.
Letters in Drug Design & Disocovery 2008, 5, 336-339.

酵素を利用したクラゲ大量処理システム
土井宏育, 岡達三
バイオサイエンスとインダストリー 2008, 66, 627-629.

放線菌が産生するプロテアーゼによるエチゼンクラゲ分解への適用
土井宏育, 岡達三, 野々村禎昭
日本水産学会誌 2008, 74, 784-795.